YahooSeptember 14, 2026 at 10:35 AM NYLast Month
Why Is BioNTech Stock Gaining Monday?
On Monday, BioNTech SE (NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lun
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
